Hudson Capital Management LLC Sells 200 Shares of Becton, Dickinson and Company (NYSE:BDX)

Hudson Capital Management LLC reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 14.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,177 shares of the medical instruments supplier’s stock after selling 200 shares during the period. Hudson Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $267,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Livelsberger Financial Advisory bought a new position in shares of Becton, Dickinson and Company in the third quarter valued at approximately $26,000. Ashton Thomas Securities LLC purchased a new stake in Becton, Dickinson and Company during the 3rd quarter valued at about $33,000. Tompkins Financial Corp grew its holdings in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares during the last quarter. Sound Income Strategies LLC increased its position in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares during the period. Finally, Kennebec Savings Bank bought a new position in Becton, Dickinson and Company during the 3rd quarter valued at approximately $46,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BDX. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Evercore ISI boosted their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus target price of $283.50.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the sale, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 2,838 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total value of $633,810.54. Following the transaction, the executive vice president now directly owns 6,141 shares in the company, valued at approximately $1,371,469.53. This trade represents a 31.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock worth $2,210,716 in the last three months. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $238.05 on Thursday. The firm has a market cap of $69.04 billion, a PE ratio of 40.08, a price-to-earnings-growth ratio of 1.72 and a beta of 0.39. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The company’s 50 day simple moving average is $227.31 and its 200-day simple moving average is $232.79. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $248.42.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the prior year, the business posted $3.42 earnings per share. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were given a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 1.75%. The ex-dividend date was Monday, December 9th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 70.03%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.